Health department will start siddha fertility clinic, says min Ma Su
Chennai: The health department will start fertility clinics under the department of Indian medicine on a pilot basis, similar to allopathic fertility clinics, at the Govt Siddha Hospital in Chennai, health minister
Ma Subramanian
said on Saturday.
The minister, who took part in a yoga demonstration as part of International Yoga Day, said the state started three allopathic fertility clinics - one each in Chennai, Coimbatore, and Salem - recognizing the increasing prevalence of infertility and the need for improved access to affordable and high-quality fertility care, as well as further research into the underlying causes and effective prevention strategies.
"I read an article by a doctor from this institution who said textbooks of siddha medicine, written centuries ago, prescribe drugs to solve infertility. We will soon start a siddha clinic for fertility on this campus," he said.
The state is also working on legislation to set up a siddha university at Madhavaram. The
Tamil Nadu Siddha Medical University Bill
, 2022, which was tabled in the state legislative assembly, was earlier withdrawn. The govt said it will undertake fresh legislation in tune with the provisions contained in the National Commission for Indian System of Medicine Act.
In 2021-2022, the govt announced it would establish a separate siddha university.
A bill passed by the Tamil Nadu assembly on April 28, 2022, was sent for the Governor's assent, but it was sent from Raj Bhavan for the assent of the President.
The Centre said certain provisions of the Tamil Nadu Siddha Medical University Bill, 2022, are not in accordance with the National Commission for Indian System of Medicine Act, 2020. "We will place the new bill in the coming assembly session," Subramanian said.
Tamil Nadu is the only state where there are govt-run colleges for five streams of Indian medicine and homeopathy. The govt will fill doctor vacancies in this stream soon.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
39 minutes ago
- Time of India
From gut health to glowing skin: Why basil seeds are a must-add to your summer diet
Basil seeds, also known as sabja seeds or tukmaria, have always kept their place for centuries in the world of natural remedies and traditional healing. These jet-black seeds are commonly used in Indian and Southeast Asian drinks as a cooling, detoxifying and nutrient-rich superfood. These seeds stand out in their adaptogenic nature, which helps the body to adapt to stress, including heat and digestive strain. The sweet basil plant seeds play a major role in Ayurvedic and Chinese medicine, offering a natural solution to common health issues in the summers, like dehydration, indigestion and skin inflammation. Explore more about the sabja seeds (basil seeds); what it contains, its value addition to your diet and its benefits. What makes basil seeds nutritionally unique Despite their small size, sabja seeds pack a potent nutritional profile. Here's what you get with every spoonful: Rich in essential minerals Basil or 'sabja' seeds are abundant in magnesium, calcium, and iron with following benefits each: Magnesium supports nerve function and muscle recovery. Calcium strengthens bones and teeth. Iron boosts hemoglobin and improves oxygen transport. This makes them an excellent natural supplement, particularly for vegans or vegetarians who may lack these minerals. Excellent source of dietary fibre Just one tablespoon provides around 7 grams of fibre, which: Improves gut health by feeding good bacteria. Regulates bowel movements, preventing constipation. Slows the release of sugar into the bloodstream, making them helpful for managing blood glucose levels. Loaded with plant antioxidants Sabja seeds contain flavonoids and polyphenols, which act as powerful antioxidants. These compounds: Fight oxidative stress, a key factor in aging and chronic disease. Possess anti-inflammatory and anti-cancer properties, according to studies published on Healthline. Plant-based Omega-3 fatty acids Unlike fish oils, sabja seeds are a vegetarian source of ALA (alpha-linolenic acid), a form of omega-3. These fatty acids: Lower inflammation. Support heart and brain health. May help in managing autoimmune disorders and mental well-being. Health benefits of basil or 'sabja' seeds in summer for skin, gut health and body wellness For gut health Basil seeds are rich in soluble fibre and have powerful digestive-supporting properties, which are especially beneficial in the heat when digestive issues tend to spike. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Perdagangkan CFD Emas dengan Broker Tepercaya IC Markets Mendaftar Undo Key benefits: Relieves acidity and bloating: The mucilaginous texture formed after soaking soothes the stomach lining and reduces inflammation. Improves bowel regularity: High fibre promotes healthy gut motility and prevents constipation—common in dehydrated summer bodies. Supports beneficial gut bacteria: Acts as a prebiotic, feeding the good bacteria in the gut for improved digestion and immunity. Flushes toxins: Helps remove waste and toxins naturally, detoxifying the digestive tract. Tip: Soak 1 tsp in water and drink it in the morning for digestive comfort all day. For skin health In hot, humid weather, skin often becomes prone to inflammation, acne, and sun damage. Basil seeds help protect the skin from within. Key benefits: Antioxidant-rich protection: Packed with flavonoids and polyphenols that fight free radicals, reducing UV-induced skin aging. Soothes inflammation: Helps reduce skin redness, puffiness, and breakouts caused by heat and sweat. Hydration support: When soaked, basil seeds retain water and help keep the body (and skin) hydrated, improving skin elasticity and glow. Natural detox: By cleansing the gut and liver, they indirectly improve skin clarity and reduce breakouts. Tip: Add coconut water or rose sherbet for a hydrating, skin-loving drink. For overall body wellness Basil seeds are adaptogens, meaning they help the body handle physical stress like heat, fatigue, and inflammation. Key benefits: Natural body coolant: Their ability to absorb water helps regulate body temperature from the inside out. Weight management: They expand in the stomach, promoting satiety and reducing summer cravings. Heart health support: Rich in omega-3 fatty acids (ALA), which reduce inflammation and support cardiovascular function. Boosts energy and immunity: Their mineral-rich profile (iron, calcium, magnesium) helps maintain energy levels and improve overall resistance to fatigue. Tip: Add to buttermilk, smoothies, or lemon water for a refreshing health boost. Ways to add basil seeds to your diet Sabja seeds are tasteless and versatile, which makes them incredibly easy to incorporate into your meals. Simple ways to add basil seeds to your diet: Soak 1 tsp in water for 15 minutes and add to lemonade, coconut water, or buttermilk. Blend into smoothies for an added health boost. Top your oatmeal or yogurt with soaked sabja seeds. Add to desserts like falooda, puddings, or chia-style parfaits. Use as a salad garnish for added fibre and texture. Sprinkle over pancakes or cereal bowls for an extra crunch. Consuming basil seeds: Precautions and tips Soak properly: Always soak sabja seeds before eating. Dry seeds can pose a choking hazard. Don't overconsume: Limit to 1-2 tablespoons per day to avoid digestive upset. Hydration is key: They work best when consumed with plenty of fluids. Also Read | Struggling with gallbladder stones? These 5 expert-recommended foods can in ease pain, and improve digestive health One step to a healthier you—join Times Health+ Yoga and feel the change
Mint
2 hours ago
- Mint
Novo Nordisk preparing to launch weight-loss drug Wegovy in India
Danish drugmaker Novo Nordisk is betting on its insulin leadership in India to dominate the country's $25-billion anti-obesity drug market with the imminent launch of its weight-loss therapy, a top company official said. Novo Nordisk is preparing to launch Wegovy in India, where millions of people are battling obesity and demand for the weight-loss drug is expected to be massive. The drug will be launched in several dosage strengths at accessible price-points. 'We are launching with full preparation and we are launching with a big bang to make it happen in India," Vikrant Shrotriya, managing director of Novo Nordisk India, told Mint in an interview. Also read: Ozempic, a patent challenge, and $25 bn race for India's weight-loss drug market Ahead of the launch, the firm has taken steps to amplify its production capacities to ensure adequate supply and believes that its position as a market leader for insulin products—used to treat and manage diabetes—in the country could give it an edge, Shrotriya said, adding that the company is gunning for a strong market share in the growing Indian anti-obesity market. Novo Nordisk, which shot to popularity through its weight-loss drugs Ozempic and Wegovy, is late to the Indian market. The company launched Ozempic in the US in 2018 and Wegovy in 2021. It lost the first-mover advantage to competitor Eli Lilly, which launched its weight-loss drug Mounjaro (Tirzepatide) in the country in March 2025. It is also staring at a loss of patent protection for Semaglutide—the compound in drugs Ozempic and Wegovy, in India in March 2026. The patent expiration will trigger a rush of generic copies from Indian companies. The company faced several supply constraints over the past few years as demand for its weight-loss drugs shot up globally. 'It was an unprecedented demand after the launch of the products," said Shrotriya, adding that the company has worked on strengthening its supply chain through investments in manufacturing capabilities across the world to plug the gaps. The company will launch Wegovy in India in five dosing strengths, as a pen-filled device, for ease of use. Novo Nordisk already has an oral form of Semaglutide, Rybelsus, in India from 2022. Rybelsus has clocked sales over ₹400 crore in India by March 2025, according to pharma data agency IQVIA. While Shrotriya declined to share the pricing for Wegovy, he said that it would have an 'India-specific" pricing strategy to boost accessibility. Also read: Sun Pharma names Kirti Ganorkar as new managing director, Dilip Shanghvi to continue as chairman Competitor Eli Lilly's drug Mounjaro, sold as a once-a-week vial injection, is priced at ₹17,500 per month. Insulin edge Shrotriya said that the company's leadership in India's insulin market will give it an edge in the anti-obesity segment as well. Novo Nordisk holds the lion's share of India's insulin market, accounting for over 50% of the market. Two of its brands, Mixtard and Ryzodeg, are among the top-selling insulin brands in India. According to pharma intelligence and B2B platform Pharmarack, India's insulin market was valued at ₹4,404 crore in April 2025. 'One out of two patients on insulin depend on us, despite having so many generic players…I think that partnership along with the doctors is something which is very close to our hearts. And that goes a long way to establish ourselves also in this new therapy area, which is obesity. So needless to say, that edge will also play a little bit to an advantage and strength," Shrotriya said. Launching ahead of the patent expiry in March 2026 will also give it an advantage. Semaglutide, the compound in Wegovy is a peptide, like insulin. 'Overall, the response to the market has been very, very good, for our insulin. And we hope to continue the same response in terms of our semaglutide even in the post-patent period," said Shrotriya. Semaglutide and Tirzepatide, which is sold by Eli Lilly under brand name Mounjaro, are GLP-1 (glucagon-like peptide-1) drugs used to treat obesity and type-2 diabetes. Earlier this year, Novo Nordisk said it would phase out pen-filled versions of its top-selling insulin brand Mixtard, which clocks ₹800 crore in annual sales. However, it will continue to sell them in vial form. Shrotriya said that the insulin market would continue to remain a focus for Novo Nordisk. 'We will continue to be a very strong player in the diabetes space with our insulin," he said. Competition in India India has a large obesity burden, with 254 million people with generalized obesity and 351 million people with abdominal obesity, according to a 2023 Indian Council of Medical Research–India Diabetes (ICMR-INDIAB) study. 'India is an unaddressed market, and will possibly be one of the countries with the highest number of patients globally…although it will take time," Shrikant Akolkar, vice-president and head of pharmaceutical research at brokerage Nuvama, told Mint. Also read: Zydus buys Agenus' biologics plants in US for $125 mn, licenses cancer therapy According to a research note by Nuvama, the Indian weight loss market is worth $25 billion and could double in size by 2033. With Novo Nordisk's drug compound Semaglutide set to lose its patent protection in the country in March 2026, several Indian players, including Dr. Reddy's, Sun Pharma, Cipla, Natco and Zydus Lifesciences are gearing up to launch cheaper generic copies of the weight-loss drug. 'The loss of patent could be a challenge for Novo Nordisk as the Indian generics will have the same active ingredient (Semaglutide). If you see global data, patients do not continue on this medicine for long, therefore if generic alternatives are available, people may look at Indian alternatives," Akolkar said. Plus, Eli Lilly's Mounjaro has already gained ground, with ₹23.94 crore in sales in just three months of launch, according to data from Pharmarack. There's a limited window for both Eli Lilly and Novo Nordisk to make money in the Indian anti-obesity market, before competitive generic alternatives enter the space, Akolkar added. Novo Nordisk's reach with doctors will give it an edge, said Akolkar. 'Novo Nordisk, through their oral drug, for the past 3-4 years of groundwork, has laid a good foundation for patient awareness and reach to the doctors. They will possibly have a very good reach and may have to convert that reach from oral to injections as a low-hanging growth opportunity for them," he said.
Time of India
2 hours ago
- Time of India
AI can transform India's healthcare sector: Apollo's Shobhana Kamineni
Shobhana Kamineni , executive chairperson, Apollo Hospitals , told ET how AI can transform India's healthcare sector more deeply than others 'We don't have enough doctors, nurses, or healthcare facilities. But we have enough people who are tech-enabled and can be upskilled,' said Shobana Kamineni, executive chairperson of Apollo HealthCo and promoter director of Apollo Hospitals. The veteran executive, the daughter of Prathap C. Reddy, the founder and chairman of Apollo Hospitals , referred to Nobel Laureate Demis Hassabis saying no invention in the world will happen without AI in future. 'So, the next vaccine or the ability to cure the disease will be AI-based because it's so much faster, it crunches so much more data.' by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Villas Prices In Dubai Might Be More Affordable Than You Think Villas In Dubai | Search Ads Get Quote Undo Although digital penetration in India remains a challenge, Kamineni pointed out that AI is no longer defined by an app, and telemedicine is just a phone call away. 'It's just a phone call to an AI system which can do the consultation and quickly send the summary to the doctor. And 80% of India's population have access to basic phones today.' She pointed out that India's demographic challenges, combined with its digital readiness, make it an ideal testbed for AI-driven healthcare models . Live Events 'We're not going to solve the problem with brick-and-mortar hospitals. We're going to solve it with smart devices and intelligent infrastructure,' she said, noting Apollo's strategy of pushing AI across both clinical and non-clinical workflows. Discover the stories of your interest Blockchain 5 Stories Cyber-safety 7 Stories Fintech 9 Stories E-comm 9 Stories ML 8 Stories Edtech 6 Stories The veteran executive, who is spearheading the healthcare giant's digital and AI-first initiatives across diagnostics, patient engagement, and hospital operations, said GenAI is enabling 7,000 Apollo doctors to improve productivity by 50%-85%. 'I can handle my 1 million patients a day with the help of technology.' She emphasized the need for ethical deployment and better regulation around patient data usage and AI safety, particularly in sensitive contexts like oncology, mental health, and chronic disease management. 'We must make sure that the data that's being used to train these models reflects the Indian genome and disease profile. That's a gap today. We cannot simply use models trained on Western populations and assume they will work here.' Kamineni also said Apollo is investing in AI-enabled doctors' assistants, remote diagnostics, and decision-support tools for clinicians to improve turnaround times and reduce burnout. 'Imagine a junior doctor who can consult an AI assistant for a differential diagnosis, or a nurse who gets real-time alerts on patient vitals before a critical event. That's not the future. It's already happening.' On the macro level, she called for public-private collaboration in creating a national AI-health data backbone - one that respects patient privacy but enables research and innovation at scale. 'This is not about competition, it's about cooperation. If India gets this right, we can build the most inclusive and efficient healthcare system in the world.'
